According to Reuters, Inspire pharmaceuticals marketed their FDA approved medication AzaSite, indicated to treat pink eye, for unapproved conditions such as blepharitis where it was not shown to be effective. This lead to doctors prescribing the medication for unapproved uses that may not have helped to improve patients conditions at all. A lawsuit against the company said that Inspire inappropriately marketed the drug from 2008 to May 2011. Currently, Merck & Co. is being held responsible for the misconduct and has agreed to pay $5.9 million since they acquired Inspire in 2011. However, a Merck spokeswoman claimed that the misconduct occurred prior to them acquiring Inspire, which they later sold in 2013 to Akorn Inc. Moving forward, it is important for doctors to be aware of the proper indications of AzaSite, which is to treat bacterial conjunctivitis, also known as pink eye.